Physician profile
James R Wright
NPI 1730256363
$3,618.48
in general payments reported to CMS, 2019-2025
20 companies · $673 in 2025
The $673 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $263 · 2021: $450 · 2022: $546 · 2023: $812 · 2024: $539 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,023.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $732.95 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $721.72 | 2019-2025 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $483.60 | 2019-2025 | Rexulti |
| Almatica Pharma LLC | $375.83 | 2022-2025 | Loreev Xr |
| Corium, LLC | $212.75 | 2022-2025 | Azstarys |
| Bausch Health US, LLC | $177.22 | 2019-2025 | Aplenzin |
| Neurocrine Biosciences, INC. | $170.97 | 2021-2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $154.64 | 2019-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $111.38 | 2019-2021 | |
| Validus Pharmaceuticals LLC | $81.20 | 2022-2025 | Equetro, Equetro, Raldesy |
| Vanda Pharmaceuticals INC. | $66.96 | 2019-2024 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.81 | 2021-2025 | Caplyta |
| Allergan, INC. | $58.03 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $50.01 | 2022-2023 | Austedo, Austedo Xr |
| Axsome Therapeutics, INC. | $44.00 | 2024-2025 | Auvelity |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $35.76 | 2019-2020 | |
| Alkermes, INC. | $30.17 | 2022 | |
| Supernus Pharmaceuticals, INC. | $19.53 | 2021 | |
| Neos Therapeutics, LP | $17.65 | 2020 | |
| Eisai INC. | $12.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.